Cpg oligodeoxynucleotides for mucosal vaccines

Mucosal Immunology, Two-Volume Set

Volumn , Issue , 2005, Pages 959-965

  Krieg, Arthur M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882831262     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012491543-5/50057-7     Document Type: Chapter

References (69)

1. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 1996, 157:1840-1845.
2. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., Wagner H., Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 2001, 98:9237-9242.
3. Biron C.A., Nguyen K.B., Pien G.C. Innate immune responses to LCMV infections: natural killer cells and cytokines. Curr. Top. Microbiol. Immunol. 2002, 263:7-27.
4. Brown W.C., Estes D.M., Chantler S.E., Kegerreis K.A., Suarez C.E. DNA and a CpG oligoncleotide derived from Babesia bovis are mitogenic for bovine B cells. Infect. Immun. 1998, 66:5423-5432.
5. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S., Raz E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 2000, 18:509-514.
6. Choi A.H., McNeal M.M., Flint J.A., Basu M., Lycke N.Y., Clements J.D., Bean J.A., Davis H.L., McCluskie M.J., VanCott J.L., Ward R.L. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 2002, 20:1733-1740.
7. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 1997, 186:1623-1631.
8. Chu R.S., McCool T., Greenspan N.S., Schreiber J.R., Harding C.V. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect. Immun. 2000, 68:1450-1456.
9. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Al-Adhani M., Kreig A.M., Cameron D.W., Heathcote J. CpG 7909, on immunostimulatory T1 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 2004, In press.
10. Davis H.L. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt. Sinai. J. Med. 1999, 66:84-90.
11. Davis H.L. Use of CpG DNA for enhancing specific immune responses. Curr. Top. Microbiol. Immunol. 2000, 247:171-183.
12. Dumais N., Patrick A., Moss R.B., Davis H.L., Rosenthal K.L. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 2002, 186:1098-1105.
13. Eastcott J.W., Holmberg C.J., Dewhirst F.E., Esch T.R., Smith D.J., Taubman M.A. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 2001, 19:1636-1642.
14. Freidag B.L., Melton G.B., Collins F., Klinman D.M., Cheever A., Stobie L., Suen W., Seder R.A. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun. 2000, 68:2948-2953.
15. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 2001, 166:3451-3457.
16. Gerber S., Lane C., Brown D.M., Lord E., DiLorenzo M., Clements J.D., Rybicki E., Williamson A.L., Rose R.C. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol. 2001, 75:4560-4752.
17. Gierynska M., Kumaraguru U., Eo S.K., Lee S., Krieg A., Rouse B.T. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J. Virol. 2002, 76:6568-6576.
18. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 2000, 164:944-953.
19. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I., Rasmussen W.L., Waldschmidt M., Sajuthi D., Purcell R.H., Davis H.L., Krieg A.M. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 2000, 164:1617-1624.
20. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
21. Horner A.A., Ronaghy A., Cheng P.M., Nguyen M.D., Cho H.J., Broide D., Raz E. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol. 1998, 190:77-82.
22. Horner A.A., Datta S.K., Takabayashi K., Belyakov I.M., Hayashi T., Cinman N., Nguyen M.D., Van Uden J.H., Berzofsky J.A., Richman D.D., Raz E. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 2001, 167:1584-1591.
23. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
24. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
25. Jiang W., Baker H.J., Smith B.F. Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective. Infect. Immun. 2003, 71:40-46.
26. Jones T.R., Obaldia N., Gramzinski R.A., Charoenvit Y., Kolodny N., Kitov S., Davis H.L., Krieg A.M., Hoffman S.L. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999, 17:3065-3071.
27. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., Hayashi T., Takabayashi K., Barenholz Y., Kedar E. Liposomal immunostimulatory DNA sequence (ISSODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002, 20:3342-3354.
28. Kadowaki N., Ho S., Antonenko S., de Waal M.R., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-870.
29. Kang S.M., Compans R.W. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol. 2003, 77:3615-3623.
30. Kim S.K., Ragupathi G., Musselli C., Choi S.J., Park Y.S., Livingston P.O. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 1999, 18:597-603.
31. Kim S.K., Ragupathi G., Cappello S., Kagan E., Livingston P.O. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000, 19:530-537.
32. Kline J.N. Effects of CpG DNA on Th1/Th2 balance in asthma. Curr. Top. Microbiol. Immunol. 2000, 247:211-225.
33. Kobayashi H., Horner A.A., Takabayashi K., Naguyen M.D., Huang E., Cinman N., Raz E. Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol. 1999, 198:69-75.
34. Kovarik J., Bozzotti P., Love-Homan L., Pihlgren M., Davis H.L., Lambert P.H., Krieg A.M., Siegrist C.A. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 1999, 162:1611-1617.
35. Kovarik J., Bozzotti P., Tougne C., Davis H.L., Lambert P.H., Krieg A.M., Siegrist C.A. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology 2001, 102:67-76.
36. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
37. Krieg A.M. From A to Z on CpG. Trends Immunol. 2002, 23:64-65.
38. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
39. Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z.K., Endres S., Krieg A.M., Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:2154-2163.
40. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., Giese T., Engelmann H., Endres S., Krieg A.M., Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 2001, 31:3026-3037.
41. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 1997, 27:2340-2344.
42. Lipford G.B., Sparwasser T., Zimmermann S., Heeg K., Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol. 2000, 165:1228-1235.
43. Magone M.T., Chan C.C., Beck L., Whitcup S.M., Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol. 2000, 30:1841-1850.
44. Mariotti S., Teloni R., von Hunolstein C., Romagnoli G., Orefici G., Nisini R. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine 2002, 20:2229-2239.
45. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 1998, 161:4463-4466.
46. McCluskie M.J., Wen Y.M., Di Q., Davis H.L. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol. 1998, 11:245-252.
47. McCluskie M.J., Weeratna R.D., Krieg A.M., Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 2000, 19:950-957.
48. McCluskie M.J., Weeratna R.D., Davis H.L. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol. Med. 2000, 6:867-877.
49. McCluskie M.J., Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 2000, 19:413-422.
50. McCluskie M.J., Weeratna R.D., Clements J.D., Davis H.L. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine 2001, 19:3759-3768.
51. McCluskie M.J., Weeratna R.D., Davis H.L. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 2001, 19:2657-2660.
52. McCluskie M.J., Weeratna R.D., Payette P.J., Davis H.L. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol. Med. Microbiol. 2002, 32:179-185.
53. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998, 16:1216-1224.
54. Olszewska W., Partidos C.D., Steward M.W. Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. Infect. Immun. 2000, 68:4923-4929.
55. Pisetsky D.S., Reich C.F. The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology 1998, 40:199-208.
56. Rankin R., Pontarollo R., Ioannou X., Krieg A.M., Hecker R., Babiuk L.A., van Drunen Littel-van den Hurk CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001, 11:333-340.
57. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 1997, 3:849-854. [see comments].
58. Ronaghy A., Prakken B.J., Takabayashi K., Firestein G.S., Boyle D., Zvailfler N.J., Roord S.T., Albani S., Carson D.A., Raz E. Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J. Immunol. 2002, 168:51-56.
59. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am. J. Respir. Cell Mol. Biol. 2000, 22:176-182.
60. Sparwasser T., Vabulas R.M., Villmow B., Lipford G.B., Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 2000, 30:3591-3597.
61. Takabayashi K., Libet L., Chisholm D., Zubeldia J., Homer A.A. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized. J. Immunol. 2003, 170:3898-3907.
62. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J., Richman D.D., Eiden J.J., Spiegelberg H.L., Raz E. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 2000, 30:1939-1947.
63. Tokunaga T., Yamamoto T., Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn. J. Infect. Dis. 1999, 52:1-11.
64. Vabulas R.M., Pircher H., Lipford G.B., Hacker H., Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J. Immunol. 2000, 164:2372-2378.
65. Vollmer J., Weeratna R.W., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H.L., Kreig A.M. Characterization of the three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34:251-262.
66. von Hunolstein C., Teloni R., Mariotti S., Recchia S., Orefici G., Nisini R. Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine. Int. Immunol. 2000, 12:295-303.
67. Wild J., Grusby M.J., Schirmbeck R., Reimann J. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. J. Immunol. 1999, 163:1880-1887.
68. Yi A.K., Hornbeck P., Lafrenz D.E., Krieg A.M. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J. Immunol. 1996, 157:4918-4925.
69. Yi A.K., Chang M., Peckham D.W., Krieg A.M., Ashman R.F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry [erratum appears in J. Immunol. 1999; 163(2):1093]. J. Immunol. 1998, 160:5898-5906.